Metro Stock or Loblaw Stock: Which Is the Better Buy?

Take a closer look at these two Canadian consumer staple stocks to determine which might be better for your portfolio right now.

| More on:

As of this writing, the S&P/TSX Composite Index is up 6.08% from its February 13 level. Before the upward trend, the Canadian benchmark index was quite volatile for over a year amid macroeconomic jitters.

The recent upward trajectory allowed many investors to realize significant capital gains on investments. Many of them missed the opportunity to buy on the dip. Then again, some stock market investors continue looking for stocks lagging behind the broader market to leverage the bull market.

However, not every investor is interested in playing with the ups and downs of a volatile market to their advantage. If you seek stable and recession-resistant stocks for your portfolio, it might be a good idea to look for opportunities in resilient sectors of the economy.

While utility stocks are excellent for this purpose, the relatively flat share price movement does not offer much in capital appreciation.

If you want to invest in recession-resistant businesses that also offer upside through capital gains, consider investing in Canadian food stocks. To this end, I will discuss two Canadian stocks you can consider for your portfolio.

Metro

Metro (TSX:MRU) is a $16.69 billion market capitalization food retailer headquartered in Montreal. The discount food and drug retail stock has a solid business that saw its quarterly revenue grow by 6.5% in its quarter that ended in 2023. In the same period, Metro stock saw same-store sales grow by 3.9% and 6.1% at pharmacies and food service outlets, respectively.

These factors from its quarterly performance suggested that the company is coming out of the inflationary rut with little more than a few scrapes. Additionally, Metro stock raised its dividend by 10.7% year over year.

The management is also committed to reducing outstanding shares, with plans to repurchase up to seven million common shares by November 24, 2024. It means the remaining shareholders will get more equity claims in the stock.

The launch of its automated fresh produce plant and automated distribution centre will lead to significant long-term profitability. As of this writing, Metro stock trades for $73.51 per share, boasting a 1.82% dividend yield.

Loblaw Companies

Loblaw Companies (TSX:L) is a Canadian retailer with a $46.45 billion market capitalization headquartered in Brampton. While Metro stock’s latest quarterly earnings report showed it recovered from the inflationary market, Loblaw stock has already recovered from almost 10 years of underperforming since 2021 to beat the gains that the former garnered in that time.

Loblaw Companies has been on a strong run for a couple of years, despite macroeconomic jitters. It opened more than 30 NoFrills and Maxi stores last year, expanding its retail footprint. It has good momentum in its bid to solidify its position as the largest drug and food retailer in Canada.

Its recent quarter saw a 2.3% and 3.7% year-over-year growth in its earnings and revenue, respectively. Its adjusted earnings per share also grew by 13.6% in the same period, showing that it is quite profitable.

With new pharmacy-based clinics lined up to drive more growth, Loblaw is also aggressively repurchasing its common shares. As of this writing, it trades for $149.84 per share, boasting a 1.19% dividend yield.

  • We just revealed five stocks as “best buys” this month … join Stock Advisor Canada to find out if Metro made the list!

Foolish takeaway

Metro stock has been repurchasing its stock aggressively in light of positive momentum for the business. However, it anticipates flat to lower earnings for fiscal 2024 due to its new launches.

While the offerings will likely drive long-term profitability for the stock, Loblaw stock anticipates faster earnings growth this year and has more bullish guidance for fiscal 2024. It might be a more attractive investment to consider between the two consumer staple stocks.

Fool contributor Adam Othman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Dividend Stocks

Concept of multiple streams of income
Dividend Stocks

A TFSA Pick Yielding 7% With Dependable Cash Payments

This TSX income fund's monthly $0.10-per-share distribution is like clockwork.

Read more »

TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins
Dividend Stocks

The Simplest and Most Effective TFSA Strategy to Kick Off 2026

Add these two TSX stocks to your self-directed TFSA portfolio to get the right mixture of defensiveness and long-term growth.

Read more »

some REITs give investors exposure to commercial real estate
Dividend Stocks

A 7.6% Dividend Stock Paying Cash Every Month

This TSX stock offers reliable monthly income with strong underlying fundamentals.

Read more »

how to save money
Dividend Stocks

A Perfect April TFSA Stock With a 4.3% Monthly Payout

This stable rental housing giant delivers consistent monthly payouts with strong fundamentals.

Read more »

trends graph charts data over time
Dividend Stocks

This TSX Dividend Stock Is Down 20% and Built for the Long Haul

This dividend-paying TSX retail stock could be a long-term winner despite recent weakness.

Read more »

Canadian Dollars bills
Dividend Stocks

The Best High-Yield Dividend Stock to Buy Right Now for Unbeatable Income

Are you looking for reliable dividends? This high-yield Canadian stock could be worth considering right now.

Read more »

Piggy bank on a flying rocket
Dividend Stocks

2 Dividend Stocks That Belong in Every Income Investor’s Portfolio

These TSX stocks have increased their dividends annually for decades.

Read more »

woman checks off all the boxes
Dividend Stocks

TFSA Investors Take Note — The CRA Is Actively Watching for These Red Flags

Holding the iShares S&P/TSX 60 Index Fund (TSX:XIU) in your TFSA can spare you scrutiny for non-approved investments.

Read more »